JonesTrading Maintains ATyr Pharma(ATYR.US) With Buy Rating, Maintains Target Price $22
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Buy Rating, Maintains Target Price $35
Positive Outlook for ATyr Pharma: Favorable Phase 3 Progress and Competitive Advantage Highlight Buy Rating
ATyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
ATyr Pharma Analyst Ratings
RBC Capital Maintains ATyr Pharma(ATYR.US) With Buy Rating, Maintains Target Price $16
RBC Capital Sticks to Its Buy Rating for ATyr Pharma (ATYR)
JonesTrading Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $22
Promising Clinical Advancements and Strong Financial Health Drive Buy Rating for ATyr Pharma
HC Wainwright & Co. Reiterates Buy on ATyr Pharma, Maintains $35 Price Target
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and ATyr Pharma (ATYR)
ATyr Pharma Analyst Ratings
Wells Fargo Initiates ATyr Pharma Overweight With $17 Price Target
Jefferies Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $9
Buy Rating on ATyr Pharma Anchored by Upcoming Clinical Trials and Strong Financials
ATyr Pharma Price Target Maintained With a $16.00/Share by RBC Capital
ATyr Pharma Analyst Ratings
RBC Capital Maintains ATyr Pharma(ATYR.US) With Buy Rating, Maintains Target Price $16
RBC Capital Reaffirms Their Buy Rating on ATyr Pharma (ATYR)
Strong Buy Rating for ATyr Pharma Amid Clinical Progress and Financial Stability